---
title: "Understanding the Market | QYUNS-B rose over 6% as the application for the marketing authorization of Ustekinumab injection was previously approved"
description: "QYUNS-B rose over 6%, as of the time of writing, up 6.67%, priced at HKD 11.2, with a transaction volume of HKD 138,600. In terms of news, QYUNS previously announced that on November 5th, Sino-America"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/220984224.md"
published_at: "2024-11-29T06:33:06.000Z"
---

# Understanding the Market | QYUNS-B rose over 6% as the application for the marketing authorization of Ustekinumab injection was previously approved

> QYUNS-B rose over 6%, as of the time of writing, up 6.67%, priced at HKD 11.2, with a transaction volume of HKD 138,600. In terms of news, QYUNS previously announced that on November 5th, Sino-American East received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), and the marketing authorization application for Ustekinumab Injection (brand name: Stelara, research code: QX001S/HDM3001) submitted by Sino-American East was approved for the treatment of adult moderate to severe plaque psoriasis. It is reported that QX001S was initially independently developed by QYUNS, and in August 2020, the company reached a cooperation agreement with Sino-American East to jointly promote the Phase III clinical trial of QX001S, with Sino-American East as the marketing authorization holder responsible for commercialization in mainland China, and SaiFushi responsible for product manufacturing and supply. QX001S is the first product in QYUNS's research pipeline to be approved for marketing and is also the first approved biosimilar of Ustekinumab Injection in China

According to Zhitong Finance APP, QYUNS-B (02509) rose over 6%, with a current increase of 6.67%, priced at HKD 11.2, and a trading volume of HKD 138,600.

In terms of news, QYUNS previously announced that on November 5th, Sino-American East received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA). The marketing authorization application for Ustekinumab Injection (trade name: Stelara, research code: QX001S/HDM3001) submitted by Sino-American East has been approved for the treatment of adult moderate to severe plaque psoriasis.

It is reported that QX001S was initially independently developed by QYUNS. In August 2020, the company reached a cooperation agreement with Sino-American East to jointly promote the Phase III clinical trial of QX001S, with Sino-American East as the marketing authorization holder responsible for commercialization in mainland China, and SaiFuShi responsible for product manufacturing and supply. QX001S is the first product in QYUNS's research pipeline to be approved for marketing and is also the first approved biosimilar of Ustekinumab Injection in China

### Related Stocks

- [02509.HK - QYUNS-B](https://longbridge.com/en/quote/02509.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued | Qyuns Therapeutics Co., Ltd. has initiated a share buyback program after the board determined that the stock is underval | [Link](https://longbridge.com/en/news/274983583.md) |
| OXY-Clean: Buffett's Favourite Oil Rig Scrubs $6 Billion In Debt Off The Books | Occidental Petroleum Corp (NYSE:OXY) has significantly reduced its debt by $5.8 billion after selling its OxyChem divisi | [Link](https://longbridge.com/en/news/276372720.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |
| Rocket Lab Corporation $RKLB Stock Holdings Increased by Vanguard Group Inc. | Vanguard Group Inc. increased its stake in Rocket Lab Corporation (NASDAQ:RKLB) by 5.4% in Q3, owning 41.8 million share | [Link](https://longbridge.com/en/news/276451972.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
